Proceedings from the third in a series of 11 integrated webinars
held in association with the 2020 ONS Annual Congress. Featuring
perspectives from Ms Kim Leake, Ms Mollie Moran, Dr Craig Moskowitz
and Dr Michael E Williams.
Introduction (00:00)
Activity and tolerability of polatuzumab vedotin for
relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
(3:25)
Overview of and clinical experience with CAR (chimeric antigen
receptor) T-cell therapy for R/R DLBCL (10:45)
Available trial data with brentuximab vedotin as a component of
up-front therapy (ECHELON-1) or as consolidation after transplant
(AETHERA) for patients with Hodgkin lymphoma (24:29)
Rationale for targeting the PD-1/PD-L1 axis in Hodgkin lymphoma
(31:29)
Case (Ms Moran): A woman in her early 30s with
Stage IV Hodgkin lymphoma treated with AVD
(doxorubicin/vinblastine/dacarbazine) and brentuximab vedotin
experiences peripheral neuropathy (34:20)
Observation versus active treatment for patients with
asymptomatic follicular lymphoma; use of subcutaneous rituximab
(41:31)
Activity and tolerability of lenalidomide/rituximab
(R2) compared to rituximab/chemotherapy for untreated
advanced-stage follicular lymphoma; approved PI3K inhibitors for
R/R disease (49:35)
Initial presentation and management of mantle cell lymphoma;
second-line therapy options (BTK inhibitors, R2,
venetoclax, et cetera) (1:01:57)
Case (Ms Leake): A man in his early 70s with
newly diagnosed mantle cell lymphoma who wishes to avoid
chemotherapy receives ibrutinib (1:13:33)
Management of lymphomas in the era of COVID-19 (1:19:04)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.